Research
Hormonal
Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).
Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.
StrongSupportsmedium confidence
From 6 to 12 months, the treatment group experienced significantly greater percentage (12.61% ± 4.11% vs. 4.84% ± 5.18%; p < 0.0001) weight loss than controls.
Why this rating
The study design is a retrospective analysis with matched controls, indicating strong evidence.
Source
Short‐Term Weight Loss Outcomes of 1.0 <scp>mg</scp> Semaglutide Therapy Initiated 6 Months After Sleeve Gastrectomy
Min He et al. · Obesity · 2025
cohort · n=136Cited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →